Savara Inc. (SVRA) is a clinical-stage biopharmaceutical company based in Yardley, Pennsylvania, focused on rare respiratory diseases. Its lead and only late-stage asset is molgramostim inhalation solution, proposed brand name MOLBREEVI, an inhaled GM-CSF therapy in development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP), a rare lung disease with no FDA-approved treatment.
Shares were down 16.51% at $4.35 shortly after the opening bell, against a previous close of $5.21. The direction is unambiguously lower. Markets are reacting to the company's pre-market announcement that the FDA will not meet its November 22, 2026 target action date for the molgramostim application and has not supplied a replacement deadline.
Savara said the agency communicated that it will not take action on the molgramostim BLA by the Prescription Drug User Fee Act target date of November 22, 2026. The review remains ongoing, and no revised action date has been provided.
The distinction matters. A missed PDUFA date is not a rejection, and the agency has not publicly identified safety, efficacy or manufacturing concerns. But the announcement removed the single most important scheduled event the stock was priced against, and it did so without substituting a new one. Investors were left with an unscheduled regulatory decision and no stated reason for the delay.
This is the second timeline slip in the application's history. The FDA had already extended the review period by three months — from August 22 to November 22, 2026 — after classifying Savara's responses to information requests as a major amendment. That extension came with an explicit note that no safety, efficacy or manufacturing issues had been raised, which makes the absence of detail this time more difficult for investors to interpret.
Savara is pre-revenue and dependent on a single asset. A delay is therefore not a timing nuisance but a funding and valuation problem: every month pushes a potential launch and any revenue further out while spending continues.
The company reported a third-quarter net loss of roughly $43.0 million and held about $129.6 million in cash, cash equivalents and short-term investments at September 30. Up to roughly $150 million of non-dilutive capital is tied to approval, including an RTW Investments royalty agreement that pays $75 million only if the FDA approves by March 31, 2027 — a date now harder to take for granted.
The reversal is sharper because of what preceded it. The stock jumped 10.4% on November 19 to $5.21 on about 9.1 million shares as traders positioned for the weekend decision date. That pre-event bid is now unwinding.
The move is idiosyncratic rather than sector-driven. The SPDR S&P Biotech ETF (XBI) was up about 0.35% and the iShares Biotechnology ETF (IBB) up about 0.64% in the same window, meaning Savara sold off against a firm sector tape.
Volume confirms conviction behind the selling. Roughly 1.6 million shares traded in the first 25 minutes, exceeding the stock's average full-day turnover of approximately 1.5 million shares across the past 70 sessions and dwarfing its typical opening volume.
Technically, the session opened at $4.18 and traded as low as $4.00, briefly undercutting the 52-week low of $4.13 before recovering. The shares are back below both their 20-day and 50-day moving averages, having lost the $5.00 handle that had framed the pre-PDUFA range.
The score runs from 0 to 100, where 0 means no meaningful news and a price move normal for the stock, and 100 means transformative news paired with an extreme, rare move. Savara lands at 75 out of 100.
The verified news is substantial but not decisive: a missed action date on the only late-stage asset of a roughly $1.1 billion biotech is material, yet the agency neither rejected the application nor disclosed concerns about the data package. The price behavior was the more extreme component. The 16.51% decline was about 6.2 times the stock's typical absolute daily move of roughly 2.7% over the past 70 sessions, and no session in that stretch produced a comparable drop. A strong catalyst and a rare move combine into the high score.
The immediate focus is a revised action date or any disclosure that the agency has requested additional information. Either would be the first real signal on the length of the delay. Beyond the US, marketing applications are under review in the UK, where a decision was expected in the fourth quarter of 2026, and in the EU, where a decision was expected in the first quarter of 2027; those timelines now carry more weight as near-term catalysts.
Investors will also scrutinize the next quarterly update for cash burn against the September 30 balance and for any change to commercial launch spending. Risks cut both ways: an approval after a short administrative delay would restore much of the lost value, while a longer review, a formal information request, or disclosure of substantive review issues would extend the funding gap. Analyst expectations remain centered on approval, but conviction now hinges on information the company has not yet provided.
Tickeron's Trending AI Robots page curates the platform's strongest automated strategies under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only top performers earn a place in this featured section. Bots differ widely by strategy, timeframe, performance metrics and traded symbols, so the selection reflects present conditions rather than a fixed list. For readers tracking volatile single-name moves like this one, reviewing the featured robots offers a structured way to compare approaches.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Indicator for SVRA moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 19 similar instances when the indicator left oversold territory. In 18 of the 19 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 70 cases where SVRA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on November 18, 2026. You may want to consider a long position or call options on SVRA as a result. In 72 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for SVRA just turned positive on November 19, 2026. Looking at past instances where SVRA's MACD turned positive, the stock continued to rise in 31 of 42 cases over the following month. The odds of a continued upward trend are 74%.
SVRA moved above its 50-day moving average on November 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +16.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where SVRA advanced for three days, in 192 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SVRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
SVRA broke above its upper Bollinger Band on November 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SVRA entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. SVRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.908) is normal, around the industry mean (3.596). P/E Ratio (-8.328) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a pharmaceuticals developer
Industry Biotechnology